- Development of glaucoma in the course of interferon alpha therapy for chronic hepatitis B
-
Kwon YS, Choe YH, Chin HS
- KMID: 720597
- Yonsei Med J.
- 2001 Feb;42(1):134-136.
- doi: 10.3349/ymj.2001.42.1.134
Previous reported ocular complications of interferon alfa administration are extremely rare. These include oculomotor palsy, corneal allograft rejection, retinal hemorrhage and cotton wool patches. A 15-year-old boy... -
- CITED
-
- Close
- SHARE
-
- Close
- Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
-
Choi JW, Lee JS, Paik WH, Song TJ, Kim JW, Bae WK, Kim KA, Kim JG
- KMID: 2363035
- Clin Mol Hepatol.
- 2016 Mar;22(1):168-171.
- doi: 10.3350/cmh.2016.22.1.168
Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
-
Varbobitis I, Papatheodoridis GV
- KMID: 2373131
- Clin Mol Hepatol.
- 2016 Sep;22(3):319-326.
- doi: 10.3350/cmh.2016.0045
Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B (CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with most studies reporting... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
-
Kim JH, Han KH, Lee KS, Park YN, Ahn SH, Chon CY, Moon YM
- KMID: 1777167
- Yonsei Med J.
- 2006 Dec;47(6):793-798.
- doi: 10.3349/ymj.2006.47.6.793
Combination therapy with interferon alpha (IFN- alpha) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%.... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent trends in the treatment of chronic hepatitis C
-
Jun DW, Tak WY, Bae SH, Lee YJ
- KMID: 1372647
- Korean J Hepatol.
- 2012 Mar;18(1):22-28.
- doi: 10.3350/kjhep.2012.18.1.22
Pegylated interferon and ribavirin combination therapy is accepted as the standard antiviral treatment for chronic hepatitis C regardless of HCV genotype. This combination therapy achieves higher response rates than previous... -
- CITED
-
- Close
- SHARE
-
- Close
- Highly effective peginterferon alpha-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
-
Yang SY, Lee HW, Lee YJ, Park SJ, Yoo KY, Kim HJ
- KMID: 2164362
- Clin Mol Hepatol.
- 2015 Jun;21(2):125-130.
- doi: 10.3350/cmh.2015.21.2.125
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between IPTA Gene Polymorphisms and Hematological Abnormalities in Hepatitis C Virus-Infected Patients Receiving Combination Therapy
-
Hwang JJ, Lo CC, Lin CH, Cheng HS, Hung IW, Tsai WJ, Hung CH
- KMID: 2380767
- Gut Liver.
- 2015 Mar;9(2):214-223.
- doi: 10.5009/gnl14095
BACKGROUND/AIMS: Hematological abnormalities during hepatitis C virus (HCV) combination therapy with pegylated interferon alpha and ribavirin often necessitate dose reduction. Variants of the ITPA gene have been reported to protect... -
- CITED
-
- Close
- SHARE
-
- Close
